{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T06:38:29Z","timestamp":1725691109767},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"8","funder":[{"name":"Research support was provided by Novartis"},{"name":"National Science and Technology Major Project","award":["2012ZX10002003"],"award-info":[{"award-number":["2012ZX10002003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1007\/s12325-015-0232-2","type":"journal-article","created":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T07:45:55Z","timestamp":1441093555000},"page":"727-741","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B"],"prefix":"10.1007","volume":"32","author":[{"given":"Jin-Lin","family":"Hou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daozheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangfeng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mobin","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deming","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lai","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junqi","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinhuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jidong","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weibin","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhong","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aldo","family":"Trylesinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolai V.","family":"Naoumov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,9,2]]},"reference":[{"key":"232_CR1","unstructured":"World Health Organization (WHO). Hepatitis B-Fact sheet. 2013. http:\/\/www.who.int\/mediacentre\/factsheets\/fs204\/en\/ . Accessed Jan 24, 2014."},{"key":"232_CR2","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/hep.1840080310","volume":"8","author":"YF Liaw","year":"1988","unstructured":"Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology. 1988;8:493\u20136.","journal-title":"Hepatology"},{"key":"232_CR3","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1136\/gut.32.3.294","volume":"32","author":"G Fattovich","year":"1991","unstructured":"Fattovich G, Brollo L, Giustina G, et al. Natural history and prognostic factors for chronic hepatitis type B. Gut. 1991;32:294\u20138.","journal-title":"Gut"},{"key":"232_CR4","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","volume":"130","author":"UH Iloeje","year":"2006","unstructured":"Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678\u201386.","journal-title":"Gastroenterology"},{"key":"232_CR5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","volume":"295","author":"CJ Chen","year":"2006","unstructured":"Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65\u201373.","journal-title":"JAMA"},{"key":"232_CR6","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.cgh.2007.06.015","volume":"5","author":"UH Iloeje","year":"2007","unstructured":"Iloeje UH, Yang HI, Jen CL, et al. Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol. 2007;5:921\u201331.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"232_CR7","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/jnci\/dji043","volume":"97","author":"MW Yu","year":"2005","unstructured":"Yu MW, Yeh SH, Chen PJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst. 2005;97:265\u201372.","journal-title":"J Natl Cancer Inst"},{"key":"232_CR8","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/j.1440-1746.2004.03360.x","volume":"19","author":"K Ohata","year":"2004","unstructured":"Ohata K, Hamasaki K, Toriyama K, Ishikawa H, Nakao K, Eguchi K. High viral load is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Gastroenterol Hepatol. 2004;19:670\u20135.","journal-title":"J Gastroenterol Hepatol"},{"key":"232_CR9","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1086\/502978","volume":"193","author":"CJ Liu","year":"2006","unstructured":"Liu CJ, Chen BF, Chen PJ, et al. Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers. J Infect Dis. 2006;193:1258\u201365.","journal-title":"J Infect Dis"},{"key":"232_CR10","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1111\/j.1572-0241.2006.00647.x","volume":"101","author":"G Chen","year":"2006","unstructured":"Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol. 2006;101:1797\u2013803.","journal-title":"Am J Gastroenterol"},{"key":"232_CR11","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12072-008-9080-3","volume":"2","author":"YF Liaw","year":"2008","unstructured":"Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2:263\u201383.","journal-title":"Hepatol Int."},{"key":"232_CR12","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jhep.2008.10.001","volume":"50","author":"European Association for the Study of the Liver","year":"2009","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227\u201342.","journal-title":"J Hepatol"},{"key":"232_CR13","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1053\/j.gastro.2008.03.003","volume":"134","author":"SL Friedman","year":"2008","unstructured":"Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008;134:1655\u201369.","journal-title":"Gastroenterology"},{"key":"232_CR14","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1053\/j.gastro.2006.09.020","volume":"131","author":"SJ Hadziyannis","year":"2006","unstructured":"Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006;131:1743\u201351.","journal-title":"Gastroenterology"},{"key":"232_CR15","doi-asserted-by":"crossref","first-page":"677","DOI":"10.7326\/0003-4819-147-10-200711200-00003","volume":"147","author":"BJ Veldt","year":"2007","unstructured":"Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007;147:677\u201384.","journal-title":"Ann Intern Med"},{"key":"232_CR16","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/hep.21492","volume":"45","author":"S Bruno","year":"2007","unstructured":"Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology. 2007;45:579\u201387.","journal-title":"Hepatology"},{"key":"232_CR17","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.gastro.2008.10.026","volume":"136","author":"YF Liaw","year":"2009","unstructured":"Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009;136:486\u201395.","journal-title":"Gastroenterology"},{"key":"232_CR18","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1056\/NEJMoa066422","volume":"357","author":"CL Lai","year":"2007","unstructured":"Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 2007;357:2576\u201388.","journal-title":"N Engl J Med"},{"key":"232_CR19","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/hep.22075","volume":"47","author":"J Hou","year":"2008","unstructured":"Hou J, Yin YK, Xu D, et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1\u00a0year of a randomized, double-blind trial. Hepatology. 2008;47:447\u201354.","journal-title":"Hepatology"},{"key":"232_CR20","doi-asserted-by":"crossref","unstructured":"Hsu CW, Chen YC, Liaw YF, et al. Prolonged efficacy and safety of 3\u00a0years of continuous telbivudine treatment in pooled data from GLOBE and 015 studies in chronic hepatitis B patients. In: European Association for the Study of the Liver (EASL), 44th Annual Meeting, Copenhagen, Denmark; April 22\u201326, 2009.","DOI":"10.1016\/S0168-8278(09)60913-2"},{"key":"232_CR21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1053\/gast.2003.50013","volume":"124","author":"JL Dienstag","year":"2003","unstructured":"Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology. 2003;124:105\u201317.","journal-title":"Gastroenterology"},{"key":"232_CR22","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/hep.22414","volume":"48","author":"P Marcellin","year":"2008","unstructured":"Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2008;48:750\u20138.","journal-title":"Hepatology"},{"key":"232_CR23","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/j.1365-2036.2005.02410.x","volume":"21","author":"MF Yuen","year":"2005","unstructured":"Yuen MF, Chow DH, Tsui K, et al. Liver histology of Asian patients with chronic hepatitis B on prolonged lamivudine therapy. Aliment Pharmacol Ther. 2005;21:841\u20139.","journal-title":"Aliment Pharmacol Ther"},{"key":"232_CR24","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/hep.23785","volume":"52","author":"TT Chang","year":"2010","unstructured":"Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis\/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52:886\u201393.","journal-title":"Hepatology"},{"key":"232_CR25","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/hep.1840010511","volume":"1","author":"RG Knodell","year":"1981","unstructured":"Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981;1:431\u20135.","journal-title":"Hepatology"},{"key":"232_CR26","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/0168-8278(95)80226-6","volume":"22","author":"K Ishak","year":"1995","unstructured":"Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696\u20139.","journal-title":"J Hepatol"},{"key":"232_CR27","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jhep.2008.02.008","volume":"48","author":"L Castera","year":"2008","unstructured":"Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol. 2008;48:835\u201347.","journal-title":"J Hepatol"},{"key":"232_CR28","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.ultrasmedbio.2003.07.001","volume":"29","author":"L Sandrin","year":"2003","unstructured":"Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003;29:1705\u201313.","journal-title":"Ultrasound Med Biol"},{"key":"232_CR29","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/liv.12480","volume":"35","author":"S Amet","year":"2015","unstructured":"Amet S, Bronowicki JP, Thabut D, et al. Prevalence of renal abnormalities in chronic HBV infection: the HARPE study. Liver Int. 2015;35:148\u201355.","journal-title":"Liver Int."},{"key":"232_CR30","doi-asserted-by":"crossref","first-page":"e646","DOI":"10.1097\/MD.0000000000000646","volume":"94","author":"X Qi","year":"2015","unstructured":"Qi X, Wang J, Chen L, et al. Impact of nucleos(t)ide analogue combination therapy on the estimated glomerular filtration rate in patients with chronic hepatitis B. Medicine (Baltimore). 2015;94:e646.","journal-title":"Medicine (Baltimore)."},{"key":"232_CR31","doi-asserted-by":"crossref","unstructured":"Ahn SH, Lee S, Park JY, et al. Comparison of the effects of telbivudine and entecavir treatment on estimated glomerular filtration rate in patients with chronic hepatitis B. Gut Liver. 2015. doi: 10.5009\/gnl14297 [Epub ahead of print].","DOI":"10.5009\/gnl14297"},{"key":"232_CR32","doi-asserted-by":"crossref","unstructured":"Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461\u201370.","DOI":"10.7326\/0003-4819-130-6-199903160-00002"},{"key":"232_CR33","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","volume":"50","author":"AS Lok","year":"2009","unstructured":"Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661\u20132.","journal-title":"Hepatology"},{"issue":"381","key":"232_CR34","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","volume":"9","author":"P Marcellin","year":"2013","unstructured":"Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;9(381):468\u201375.","journal-title":"Lancet"},{"key":"232_CR35","doi-asserted-by":"crossref","first-page":"S388","DOI":"10.1016\/S0168-8278(10)61007-0","volume":"52","author":"EJ Gane","year":"2010","unstructured":"Gane EJ, Marcellin P, Jacobson I, Heathcoate EJ, Dusheiko G, de Man R. HBsAg kinetics of decay and baseline characteristics of HBeAg-positive patients with chronic hepatitis B following 3\u00a0years of tenofovir disoproxil fumarate (TDF) treatment [Abstract]. J Hepatol. 2010;52:S388.","journal-title":"J Hepatol"},{"key":"232_CR36","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1365-2893.2009.01146.x","volume":"17","author":"RG Gish","year":"2010","unstructured":"Gish RG, Chang TT, Lai CL, et al. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naive HBeAg-positive patients with chronic hepatitis B. J Viral Hepat. 2010;17:16\u201322.","journal-title":"J Viral Hepat."},{"key":"232_CR37","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1002\/hep.23905","volume":"52","author":"K Wursthorn","year":"2010","unstructured":"Wursthorn K, Jung M, Riva A, et al. Kinetics of hepatitis B surface antigen decline during 3\u00a0years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology. 2010;52:1611\u201320.","journal-title":"Hepatology"},{"key":"232_CR38","unstructured":"Gane E, Deray G, Piratvisuth T, et al. Renal function is improved for Chronic Hepatitis B (CHB) patients treated with telbivudine. In: 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, CA, USA; November 4\u20138, 2011. Poster #1439."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-015-0232-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T14:42:01Z","timestamp":1498228921000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-015-0232-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["232"],"URL":"https:\/\/doi.org\/10.1007\/s12325-015-0232-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8]]}}}